| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT02422615 |
| P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
| P17 | country | Canada | Q16 |
| Norway | Q20 | ||
| Hungary | Q28 | ||
| Spain | Q29 | ||
| United States of America | Q30 | ||
| Belgium | Q31 | ||
| Sweden | Q34 | ||
| Denmark | Q35 | ||
| Poland | Q36 | ||
| Italy | Q38 | ||
| Switzerland | Q39 | ||
| Austria | Q40 | ||
| Turkey | Q43 | ||
| Portugal | Q45 | ||
| Netherlands | Q55 | ||
| Mexico | Q96 | ||
| France | Q142 | ||
| United Kingdom | Q145 | ||
| Germany | Q183 | ||
| Bulgaria | Q219 | ||
| Singapore | Q334 | ||
| Australia | Q408 | ||
| Argentina | Q414 | ||
| Colombia | Q739 | ||
| Jordan | Q810 | ||
| Lebanon | Q822 | ||
| Malaysia | Q833 | ||
| Thailand | Q869 | ||
| P582 | end time | 2017-11-03 | |
| P921 | main subject | breast cancer | Q128581 |
| multiple endocrine neoplasia | Q1553018 | ||
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 726 | |
| P4844 | research intervention | hormones, hormone substitutes, and hormone antagonists | Q50430050 |
| hormonal antineoplastic agent | Q50430266 | ||
| hormone antagonist | Q16875676 | ||
| P6153 | research site | University of Florida | Q501758 |
| Novartis | Q507154 | ||
| P1813 | short name | MONALEESA-3 | |
| P859 | sponsor | Novartis | Q507154 |
| P580 | start time | 2015-06-09 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment |
Search more.